 |
인쇄하기
취소
|
Drug agency to probe safety of Levovir
The Korea Food and Drug Administration has recently announced it will examine on May 2 the safety of Levovir (clevudine) that is confirmed to have caused serious myopathy in patients with hepatitis B.
The announcement comes as the US based Pharmasset terminated its phase III clinical trial due to some myopathy cases in patients.
The KFDA will be given advice from the Central Pharmaceutica...
The announcement comes as the US based Pharmasset terminated its phase III clinical trial due to some myopathy cases in patients.
The KFDA will be given advice from the Central Pharmaceutica...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.